Tandem Diabetes Care Inc (NASDAQ:TNDM) reported its financial results for the quarter ended March 31, 2014. For the quarter ended March 31, 2014, sales grew 48 percent to $8.1 million, compared to $5.5 million for the same period of 2013. For the quarter ended March 31, 2014, pump shipments grew 102 percent to 1,723 t:slim Pumps, compared to 852 pumps for the same period of 2013. The growth rate for pump shipments exceeded the growth rate for sales, primarily due to $1.9 million of t:slim Pump sales recognized in the first quarter 2013 that were shipped in the fourth quarter of 2012. The sales were recognized in the first quarter of 2013 as a result of the t:slim Pump’s 30-day return policy and a lack of product returns history at the time of shipment. Tandem Diabetes Care Inc (NASDAQ:TNDM) weekly performance is 3.86%. On last trading day company shares ended up $16.94. Analysts mean target price for the company is $25.20. Tandem Diabetes Care Inc (NASDAQ:TNDM) distance from 50-day simple moving average (SMA50) is -2.96%.
Accelerate Diagnostics (NASDAQ:AXDX) major shareholder Larry N. Feinberg acquired 297,618 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $16.80 per share, for a total transaction of $4,999,982.40. Following the transaction, the insider now directly owns 21,278 shares in the company, valued at approximately $357,470. Accelerate Diagnostics Inc (NASDAQ:AXDX) shares fell -5.10% in last trading session and ended the day on $23.62. AXDX return on assets is -45.00%. Accelerate Diagnostics Inc (NASDAQ:AXDX) quarterly performance is 50.93%.
Revance Therapeutics Inc (NASDAQ:RVNC) shares closed $28.65 in last trading session, while 52 week range of $21.00 – $39.86. Revance Therapeutics Inc (NASDAQ:RVNC) year to date (YTD) performance is 6.70%.
On June 2, 2014, Lpath, Inc. (NASDAQ:LPTN), will present a Trial-in-Progress poster at the American Society of Clinical Oncology (ASCO) meeting in Chicago. The poster, “A Multi-Center, Open Label, Single-Arm, Phase 2 Study of the S1P Inhibitor Sonepcizumab (ASONEP) in Patients with Previously Treated Metastatic Renal Cell Carcinoma (mRCC),” presented between 1:15 p.m. and 5:00 p.m. CDT in the genitourinary (non-prostate) cancer session. The primary author is Rupal Bhatt, M.D., Ph.D. from Beth Israel Deaconess Medical Center in Boston. Lpath, Inc. (NASDAQ:LPTN) ended the last trading day at $3.91. Company weekly volatility is calculated as 5.33% and price to cash ratio as 3.79. Lpath, Inc. (NASDAQ:LPTN) showed a positive weekly performance of -1.26%.
On June 5, 2014, Amedica Corporation (NASDAQ:AMDA), announced that it will cease distribution of amniotic derived allograft products under a distribution agreement with a third party supplier. Amedica Corporation (NASDAQ:AMDA) weekly performance is -16.90%. On last trading day company shares ended up $4.77. Analysts mean target price for the company is $11.50. Amedica Corporation (NASDAQ:AMDA) distance from 50-day simple moving average (SMA50) is -27.90%.